|
Jul 16
|
Crinetics Pharmaceuticals (CRNX) Gets Initiated With a Hold Rating at Goldman Sachs
|
|
Jul 13
|
Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025
|
|
Jul 11
|
Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
|
|
Jul 10
|
Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Jul 8
|
Should You Hold Crinetics Pharmaceuticals (CRNX)?
|
|
Jun 30
|
Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
|
|
Mar 10
|
Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Feb 20
|
Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences
|
|
Feb 10
|
Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Feb 6
|
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
|
|
Feb 5
|
Crinetics Pharmaceuticals, Inc. (CRNX): One of January’s Biggest Losers
|